Back to Search Start Over

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.

Authors :
Kho S
Seung KJ
Huerga H
Bastard M
Khan PY
Mitnick CD
Rich ML
Islam S
Zhizhilashvili D
Yeghiazaryan L
Nikolenko EN
Zarli K
Adnan S
Salahuddin N
Ahmed S
Vargas ZHR
Bekele A
Shaimerdenova A
Tamirat M
Gelin A
Vilbrun SC
Hewison C
Khan U
Franke M
Source :
Nature communications [Nat Commun] 2024 May 09; Vol. 15 (1), pp. 3927. Date of Electronic Publication: 2024 May 09.
Publication Year :
2024

Abstract

Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT03259269) to estimate the frequency (primary endpoint) among individuals receiving a longer (18-to-20 month) regimen for multidrug- or rifampicin-resistant (MDR/RR) TB who experienced culture conversion. We also conduct Cox proportional hazard regression analyses to identify factors associated with reversion, including comorbidities, previous treatment, cavitary disease at conversion, low body mass index (BMI) at conversion, time to conversion, and number of likely-effective drugs. Of 1,286 patients, 54 (4.2%) experienced reversion, a median of 173 days (97-306) after conversion. Cavitary disease, BMI < 18.5, hepatitis C, prior treatment with second-line drugs, and longer time to initial culture conversion were positively associated with reversion. Reversion was uncommon. Those with cavitary disease, low BMI, hepatitis C, prior treatment with second-line drugs, and in whom culture conversion is delayed may benefit from close monitoring following conversion.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2041-1723
Volume :
15
Issue :
1
Database :
MEDLINE
Journal :
Nature communications
Publication Type :
Academic Journal
Accession number :
38724531
Full Text :
https://doi.org/10.1038/s41467-024-48077-8